PubRank

Alan S Perelson

Author PubWeight™ 297.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008 16.54
2 Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009 7.01
3 The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009 6.22
4 Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008 5.24
5 Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009 4.79
6 A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003 4.12
7 Kinetics of influenza A virus infection in humans. J Virol 2006 3.78
8 High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 2010 3.68
9 Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007 3.24
10 Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 2010 3.02
11 Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014 2.95
12 Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010 2.82
13 Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013 2.79
14 Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004 2.74
15 Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003 2.50
16 Modeling sequence evolution in acute HIV-1 infection. J Theor Biol 2009 2.32
17 Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012 2.27
18 The complexity of complexes in signal transduction. Biotechnol Bioeng 2003 2.20
19 Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 2012 2.05
20 Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004 2.05
21 Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol 2003 2.03
22 Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 2010 2.02
23 Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006 2.01
24 Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007 2.00
25 CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 2010 1.99
26 Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003 1.90
27 Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007 1.89
28 Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 2011 1.88
29 Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011 1.87
30 Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol 2003 1.87
31 In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A 2002 1.82
32 Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 2010 1.80
33 Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 2009 1.78
34 Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol 2004 1.77
35 Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol 2009 1.76
36 Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007 1.74
37 ON IDENTIFIABILITY OF NONLINEAR ODE MODELS AND APPLICATIONS IN VIRAL DYNAMICS. SIAM Rev Soc Ind Appl Math 2011 1.69
38 Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006 1.69
39 Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 2007 1.68
40 Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2013 1.63
41 Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012 1.61
42 Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol 2005 1.60
43 Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol 2011 1.57
44 Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull Math Biol 2008 1.56
45 Drug resistance and influenza pandemics. Lancet 2002 1.55
46 Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2007 1.54
47 Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol 2006 1.53
48 In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol 2003 1.53
49 Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr 2005 1.52
50 Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003 1.51
51 Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol 2008 1.51
52 Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 2008 1.51
53 Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 2009 1.49
54 Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol 2008 1.49
55 Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A 2007 1.48
56 Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005 1.47
57 HIV-1 infection and low steady state viral loads. Bull Math Biol 2002 1.46
58 Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002 1.45
59 Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics 2010 1.45
60 Agent-based modeling of host-pathogen systems: The successes and challenges. Inf Sci (Ny) 2009 1.43
61 Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol 2004 1.43
62 Complete genetic linkage can subvert natural selection. Proc Natl Acad Sci U S A 2007 1.42
63 Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci 2002 1.41
64 Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol 2006 1.41
65 Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol 2008 1.39
66 Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol 2004 1.39
67 HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A 2005 1.36
68 Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A 2011 1.36
69 Quantifying T lymphocyte turnover. J Theor Biol 2013 1.35
70 Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol 2006 1.35
71 Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol 2006 1.31
72 Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012 1.30
73 Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 2002 1.30
74 Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003 1.30
75 Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol 2011 1.28
76 Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog 2012 1.28
77 Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003 1.27
78 Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol 2012 1.26
79 Characterizing T cell movement within lymph nodes in the absence of antigen. J Immunol 2007 1.24
80 Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 2013 1.23
81 Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection. J Acquir Immune Defic Syndr 2006 1.23
82 Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther 2004 1.23
83 Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol 2009 1.23
84 Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data. Immunol Rev 2007 1.23
85 Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 2009 1.22
86 Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008 1.21
87 Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 2006 1.21
88 How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol 2008 1.20
89 Dynamics of hepatitis B virus infection. Microbes Infect 2002 1.20
90 A stochastic model of cytotoxic T cell responses. J Theor Biol 2004 1.20
91 The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci U S A 2007 1.19
92 Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med 2010 1.18
93 Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003 1.18
94 Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002 1.18
95 Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Bull Math Biol 2008 1.17
96 Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 2013 1.16
97 Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput Biol 2011 1.15
98 Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput Biol 2010 1.15
99 Dynamics of T- and B-lymphocyte turnover in a natural host of simian immunodeficiency virus. J Virol 2007 1.15
100 Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci 2004 1.14
101 Viral dynamics during primary simian immunodeficiency virus infection: effect of time-dependent virus infectivity. J Virol 2010 1.14
102 Understanding the mechanisms and limitations of immune control of HIV. Immunol Rev 2007 1.13
103 Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol 2013 1.12
104 Estimating average cellular turnover from 5-bromo-2'-deoxyuridine (BrdU) measurements. Proc Biol Sci 2003 1.11
105 Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003 1.11
106 A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 2009 1.11
107 Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol 2005 1.10
108 Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology 2012 1.10
109 Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modeling. J Virol 2010 1.09
110 Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. J Hepatol 2012 1.09
111 Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2012 1.09
112 Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 2009 1.08
113 Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007 1.08
114 Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012 1.08
115 Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther 2012 1.07
116 Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol 2004 1.06
117 Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. Curr Hepat Rep 2011 1.06
118 Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 2009 1.05
119 Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. J Gen Virol 2008 1.05
120 Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 2008 1.05
121 Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull Math Biol 2007 1.05
122 High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control. J Virol 2005 1.05
123 Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci 2008 1.05
124 Precise determination of time to reach viral load set point after acute HIV-1 infection. J Acquir Immune Defic Syndr 2012 1.05
125 Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn 2006 1.05
126 Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 2012 1.04
127 Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012 1.04
128 An accurate two-phase approximate solution to an acute viral infection model. J Math Biol 2009 1.03
129 A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS One 2011 1.03
130 Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol 2010 1.02
131 Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol 2011 1.02
132 Modeling deuterated glucose labeling of T-lymphocytes. Bull Math Biol 2002 1.02
133 Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 2004 1.01
134 The probability of HIV infection in a new host and its reduction with microbicides. Math Biosci 2008 1.00
135 A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 2008 1.00
136 Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. J Immunol 2002 0.99
137 Some scaling principles for the immune system. Immunol Cell Biol 2004 0.97
138 Modelling deuterium labelling of lymphocytes with temporal and/or kinetic heterogeneity. J R Soc Interface 2012 0.97
139 Stochastic models of lymphocyte proliferation and death. PLoS One 2010 0.96
140 Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 2011 0.95
141 Analysis of human immunodeficiency virus cytopathicity by using a new method for quantitating viral dynamics in cell culture. J Virol 2005 0.95
142 Evaluation of multitype mathematical models for CFSE-labeling experiment data. Bull Math Biol 2011 0.95
143 Modeling T cell proliferation and death in vitro based on labeling data: generalizations of the Smith-Martin cell cycle model. Bull Math Biol 2007 0.95
144 Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility. J Theor Biol 2007 0.95
145 Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors. J Immunol 2011 0.95
146 The effects of thymic selection on the range of T cell cross-reactivity. Eur J Immunol 2005 0.94
147 Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 2014 0.94
148 Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 2004 0.94
149 Effects of aging on influenza virus infection dynamics. J Virol 2014 0.94
150 Modeling the effects of vaccination on chronically infected HIV-positive patients. J Acquir Immune Defic Syndr 2002 0.94
151 Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand-receptor interactions: theory and application to HIV treatment. Math Biosci 2002 0.94
152 Stochastic model of an influenza epidemic with drug resistance. J Theor Biol 2007 0.93
153 An age-structured model of hiv infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells. Math Biosci Eng 2004 0.93
154 The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol 2003 0.93
155 Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 2010 0.93
156 Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 2007 0.92
157 Inferring HIV Escape Rates from Multi-Locus Genotype Data. Front Immunol 2013 0.91
158 Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 2005 0.91
159 Optimal viral production. Bull Math Biol 2003 0.90
160 Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep 2008 0.90
161 Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol 2011 0.89
162 Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J Virol 2004 0.89
163 Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol 2012 0.88
164 Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin Liver Dis 2003 0.88
165 Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol 2010 0.88
166 Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 2007 0.87
167 ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS. SIAM J Appl Math 2009 0.87
168 Mathematical modeling of HCV infection and treatment. Methods Mol Biol 2009 0.87
169 Towards multiscale modeling of influenza infection. J Theor Biol 2013 0.87
170 Backward bifurcations and multiple equilibria in epidemic models with structured immunity. J Theor Biol 2008 0.87
171 Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis 2013 0.87
172 Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology 2014 0.86
173 Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved. Hepatology 2011 0.86
174 Interpreting CFSE obtained division histories of B cells in vitro with Smith-Martin and cyton type models. Bull Math Biol 2009 0.85
175 Viral kinetic modeling: state of the art. J Pharmacokinet Pharmacodyn 2014 0.85
176 Hepatitis B virus clearance rate estimates. Hepatology 2009 0.84
177 Effect of target cell availability on HIV-1 production in vitro. AIDS 2002 0.84
178 Liver transplantation with hepatitis C virus-infected graft: interaction between donor and recipient viral strains. Hepatology 2003 0.84
179 Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Antivir Ther 2014 0.84
180 Persistence and emergence of X4 virus in HIV infection. Math Biosci Eng 2011 0.83
181 Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology 2007 0.83
182 Contribution of follicular dendritic cells to persistent HIV viremia. J Virol 2013 0.83
183 Mutagenic effects of ribavirin in vivo. J Hepatol 2005 0.83
184 Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS 2015 0.82
185 Stochastic stage-structured modeling of the adaptive immune system. Proc IEEE Comput Soc Bioinform Conf 2003 0.82
186 Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 2009 0.82
187 Duration of an intermittent episode of viremia. Bull Math Biol 2005 0.82
188 Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther 2014 0.82
189 Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World J Gastroenterol 2007 0.81
190 Modeling and simulation of aggregation of membrane protein LAT with molecular variability in the number of binding sites for cytosolic Grb2-SOS1-Grb2. PLoS One 2012 0.81
191 Modelling the impact of antigen kinetics on T-cell activation and response. Immunol Cell Biol 2004 0.81
192 The life span of ganglionic glia in murine sensory ganglia estimated by uptake of bromodeoxyuridine. Exp Neurol 2004 0.81
193 Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci 2013 0.80
194 Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches. Semin Immunol 2013 0.80
195 Spontaneous clearance of viral infections by mesoscopic fluctuations. PLoS One 2012 0.79
196 Dynamics of CD4(+) T cell responses against Listeria monocytogenes. J Immunol 2012 0.79
197 Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection. PLoS Comput Biol 2009 0.79
198 Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy. Proc Natl Acad Sci U S A 2011 0.78
199 Dynamic characteristics of HIV-1 reservoirs. Curr Opin HIV AIDS 2006 0.78
200 The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert Rev Gastroenterol Hepatol 2013 0.77
201 Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase. J Hepatol 2002 0.77
202 Modeling sequence evolution in HIV-1 infection with recombination. J Theor Biol 2013 0.76
203 Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis 2006 0.76
204 A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antivir Ther 2014 0.76
205 Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. J Virol 2013 0.76
206 Antigen-stimulated CD4 T cell expansion can be limited by their grazing of peptide-MHC complexes. J Immunol 2013 0.75
207 The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection. Virology 2008 0.75
208 HIV-1 viral dynamics studies in the setting of clinical trials--A window of opportunity. J Infect Dis 2007 0.75
209 The extrahepatic contribution to HCV plasma viremia. J Hepatol 2006 0.75
210 Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. Antivir Ther 2015 0.75
211 Corrigendum: Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat Med 2017 0.75